United States Patent and Trademark Office

Phenomix Sciences Co-Founders Awarded First Patent for Using Precision Medicine and Phenotyping to Treat Obesity

Retrieved on: 
Thursday, September 28, 2023
Patent, Mayo Clinic, Obesity, Diet, Single-nucleotide polymorphism, United States Patent and Trademark Office, Weight gain, Hormone, Patient, Medicine, Phenotype, Gene, Disease, Soft drink, Pharmaceutical industry

MENLO PARK, Calif., Sept. 28, 2023 /PRNewswire/ -- Phenomix Sciences (Phenomix), a precision medicine biotechnology company that brings data-driven precision medicine to obesity treatment, announced today the United States Patent and Trademark Office (USPTO) has issued the first patent related to its obesity phenotyping technology.

Key Points: 
  • MENLO PARK, Calif., Sept. 28, 2023 /PRNewswire/ -- Phenomix Sciences (Phenomix), a precision medicine biotechnology company that brings data-driven precision medicine to obesity treatment, announced today the United States Patent and Trademark Office (USPTO) has issued the first patent related to its obesity phenotyping technology.
  • The patent applications are directed to various aspects of personalized obesity medicine, including foundational obesity phenotyping technology, analytical and computer implemented methods, phenotype-related lifestyle interventions and specific predictors of drug response.
  • "This patent serves as a testament to the value of obesity phenotyping and the substantial contributions it offers in addressing the disease."
  • "This first patent grant is the first of numerous patents filed, covering the strides made in obesity phenotyping over the past five years.

ZAP Surgical Deals Two More Blows to Elekta in IP Suit, Removing Barriers to Mass Adoption of the ZAP-X Radiosurgery Platform

Retrieved on: 
Thursday, September 28, 2023
Legal, Technology, Surgery, Medical Devices, Health Technology, Professional Services, Biotechnology, Health, Robotics, Patent, Radiation, Failure, United States Patent and Trademark Office, Federal Patent Court (Germany), Federal court, Stanford University, Medicine, Judgement, Appeal, IAEA, Patient, ZAP, Isotope, 3D printing, Elekta, Neurosurgery

In April 2019, Elekta alleged that the ZAP-X infringed upon its patent 7,296,648, which described a theoretical design for a radiosurgery device that was never brought to market.

Key Points: 
  • In April 2019, Elekta alleged that the ZAP-X infringed upon its patent 7,296,648, which described a theoretical design for a radiosurgery device that was never brought to market.
  • Elekta’s lawsuit against ZAP Surgical sought monetary damages with a three-fold enhancement for willful infringement, as well as an injunction prohibiting the importation, manufacture, use and sales of the ZAP-X.
  • The judicial panel meticulously reviewed Elekta's arguments and found them “unpersuasive”, thus settling the matter conclusively in favor of ZAP Surgical.
  • This German decision echoes the sentiments expressed by the U.S. courts, further strengthening ZAP Surgical's position in this protracted legal battle.

OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update

Retrieved on: 
Wednesday, September 27, 2023
Oncology, Health, Clinical Trials, Research, Science, Biotechnology, GDI Integrated Facility Services, Failure, DSMB, Data science, I&I, Head, Teaching hospital, Patent, Patient, Artificial intelligence, Kidney transplantation, OSE, Real, Physician, Lung cancer, EMA, Boehringer Ingelheim, RNA therapeutics, Lymphoma, Interleukin 7, FDA, Pancreatic cancer, AACR, International, ICI, United States Patent and Trademark Office, Cancer, Hook effect, Biomarker, Immunotherapy, Antibody, Ulcerative colitis, Transplant, Therapy, Partnership, CD28, IBD, IO, RNA, ASCO, American Society of Clinical Oncology, First, ISIN, Poster, AI, Society, Pharmaceutical industry, Vaccine, Medical imaging, Fine chemical, NSCLC

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces its consolidated half-year financial results and provides updates on key milestones achieved during H1 2023 as well as the Company’s outlook for its immunotherapies in immuno-oncology and immuno-inflammation.

Key Points: 
  • OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces its consolidated half-year financial results and provides updates on key milestones achieved during H1 2023 as well as the Company’s outlook for its immunotherapies in immuno-oncology and immuno-inflammation.
  • Eric Leire was appointed independent Director of OSE Immunotherapeutics on June 22, 2023.
  • Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, was appointed as Director and Anne-Laure Autret-Cornet, Chief Financial Officer, as Director representing the employee shareholders.
  • The key figures of the 2023 consolidated half-year results are reported below:

EVERI PAYMENTS INC. ANNOUNCES RECENT SUCCESS IN THE MATTER OF Everi Payments Inc. ("Petitioner") v. Sightline Payments LLC ("Patent Owner") HELD BEFORE THE USPTO, PATENT TRIAL AND APPEAL BOARD

Retrieved on: 
Tuesday, September 26, 2023
Uncertainty, E pluribus unum, Fintech, PTAB, United States Patent and Trademark Office, District court, Patent, Douglas v. U.S. District Court ex rel Talk America, NYSE, Everi Holdings, Sightline (architecture)

Patent Owner Sightline Payments LLC (hereinafter "Sightline") originally filed a lawsuit against Everi and its affiliate in the U.S. District Court for the Western District of Texas: Sightline Payments LLC v. Everi Holdings Inc., et al, No.

Key Points: 
  • Patent Owner Sightline Payments LLC (hereinafter "Sightline") originally filed a lawsuit against Everi and its affiliate in the U.S. District Court for the Western District of Texas: Sightline Payments LLC v. Everi Holdings Inc., et al, No.
  • In the Texas Action, Sightline alleged that Everi's "Cash Club Wallet" product infringed upon certain claims in five patents owned by Sightline (collectively, the "Sightline Patents").
  • Kate Lowenhar-Fisher, Chief Legal Officer of Everi, said, "Everi is gratified that after reviewing all of the facts and testimony, the PTAB found in our favor.
  • Our company will continue to provide its best-in-class technology while respecting the valid intellectual property rights of others."

electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology

Retrieved on: 
Tuesday, September 26, 2023
United States Patent and Trademark Office, 1836 U.S. Patent Office fire, Seizure, Patent, ECOR, ElectroCore, NVN, Use, 3D printing, Medical device

ROCKAWAY, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to non-invasive nerve stimulation with mobile devices.

Key Points: 
  • ROCKAWAY, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to non-invasive nerve stimulation with mobile devices.
  • U.S. Patent No.
  • “We continue to broaden our intellectual property portfolio and strengthen our position around systems utilizing mobile devices to control stimulators,” stated Dan Goldberger, Chief Executive Officer of electroCore.
  • “The addition of this new patent is an example of how electroCore’s nVNS technology may be expanded in the future to cover neurological and psychiatric conditions, and how our robust patent portfolio covering the use of mobile devices to operate a nerve stimulator may be leveraged in our new suite of products and devices.”

Peak Bio, Inc. Announces Filing of Provisional Patent Applications for PH-1, a Novel and Specific Immunomodulatory ADC payload platform targeting RNA splicing

Retrieved on: 
Tuesday, September 19, 2023
Patent, AACR, Doctor of Pharmacy, Therapy, United States Patent and Trademark Office, CMC, SF3B1, PH1, Cancer, MBA, Biological patents in the United States, Patient, PH-1, OTC, ADC, Spacecraft, Pharmaceutical industry, Fine chemical

Peak Bio, Inc. today announced that it has filed provisional patent applications with the United States Patent and Trademark Office (USPTO) covering claims for the Company’s potent Thailanstatin payload platform specific to the spliceosome protein, SF3B1.

Key Points: 
  • Peak Bio, Inc. today announced that it has filed provisional patent applications with the United States Patent and Trademark Office (USPTO) covering claims for the Company’s potent Thailanstatin payload platform specific to the spliceosome protein, SF3B1.
  • These patent applications are the second set of applications related to the Company’s R&D toxin portfolio on Thailanstatin, termed PH-1.
  • Previously, the USPTO had issued a patent (Patent No.
  • US 10,815,246 B2) covering potent Thailanstatin drug payloads, non-cleavable and cleavable linkers, and antibody-drug conjugate (ADC) technology derived from it.

edatanetworks Inc. Receives Multiple Patent Approvals from USPTO for Artificial Intelligence with Digital Commerce for Community

Retrieved on: 
Thursday, September 21, 2023
Other Philanthropy, Electronic Commerce, Technology, Digital Marketing, Data Analytics, Content Marketing, Business, Fintech, Small Business, Marketing, Finance, Advertising, Communications, Banking, Professional Services, Artificial Intelligence, Philanthropy, Software, Fund Raising, Internet, Foundation, United States Patent and Trademark Office, Patent, Artificial intelligence, Organization, Ecosystem, Intelligence, Algorithm, Retail

edatanetworks Inc. announced today that five (5) additional patents have been approved by the United States Patent and Trademark Office (USPTO).

Key Points: 
  • edatanetworks Inc. announced today that five (5) additional patents have been approved by the United States Patent and Trademark Office (USPTO).
  • These patents relate to artificial intelligence, rich transactional data, augmented reality, as well as automated enrollment while directing merchant micro-donations that benefit local non-profits and foundations.
  • The approved patent 11,763,336 discloses the use of artificial intelligence to establish customer segmentations with detailed consumer personas.
  • These enable local businesses to define incentives that are targeted and relevant to consumers based on community and philanthropic preferences.

Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates

Retrieved on: 
Wednesday, September 20, 2023
Mental Health, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Psilocybin, Patent, Hallucination, Depression, Therapy, Anxiety, United States Patent and Trademark Office, Addiction, Patient, Family, Pharmaceutical industry, Enver Gjokaj

11,752,130, titled “Carboxylated Psilocybin Derivatives and Methods of Using,” pertaining to the Company’s EVM301 Series of molecules being developed as potential treatments for mental health disorders.

Key Points: 
  • 11,752,130, titled “Carboxylated Psilocybin Derivatives and Methods of Using,” pertaining to the Company’s EVM301 Series of molecules being developed as potential treatments for mental health disorders.
  • This new patent, issued September 12, 2023, provides Enveric with intellectual property rights with claims to novel compositions and pharmaceutical drug formulations for a family of carboxylated derivatives of tryptamine-based drug candidates.
  • The Company expects the patent to further strengthen and add value to Enveric’s EVM301 Series of compounds, which are undergoing lead optimization and preclinical candidate characterization procedures.
  • For these reasons, Enveric is seeking to build a robust intellectual property portfolio for our EVM301 Series with this U.S. patent providing a critical IP cornerstone.”

2023 Collegiate Inventors Competition Finalists Show Future of American Innovation

Retrieved on: 
Thursday, September 21, 2023
Rhea, Failure, Intellectual property, Privacy, Hospital, Patient, Risk, United States Patent and Trademark Office, Health, Nanotechnology, Collegiate, Commerce, Tissue, Arrow Electronics, Patent, Human, OLV, Lipopolysaccharide, Immunity, Research, Biomedical engineering, Invention, Death, Montreal, FLASH, Cervical cancer, Diagnosis, Aneurysm, Game Developers Choice Awards, Pap test, Skin, Safety, Vaccine, Poultry, Cancer, National Collegiate Inventors and Innovators Alliance, Under Secretary of Commerce for Intellectual Property, Cell, DSM-IV codes, Rupture, Water, Papanikolaou, National Inventors Hall of Fame, CRISPR, Surgeon, Probability, PAP, Infection, Achilles tendon rupture, Septic shock, Pain, Student, Nucleotide, Farm, Management, Birth control, Medical imaging

NORTH CANTON, Ohio, Sept. 21, 2023 /PRNewswire/ -- The Collegiate Inventors Competition® , an annual competition that has rewarded innovations, discoveries and research by college and university students and their faculty advisers for more than 30 years, announced today its 2023 finalists.

Key Points: 
  • NORTH CANTON, Ohio, Sept. 21, 2023 /PRNewswire/ -- The Collegiate Inventors Competition® , an annual competition that has rewarded innovations, discoveries and research by college and university students and their faculty advisers for more than 30 years, announced today its 2023 finalists.
  • This year's finalists and their inventions provide a glimpse into the future of American innovation and emerging technological trends — from providing immunity from avian influenza to hunger-regulating hormone modulation.
  • "The USPTO is proud to host the 2023 Collegiate Inventors Competition — a program where the brightest college minds will showcase inventions that will shape the future of American innovation," said Kathi Vidal, Under Secretary of Commerce for Intellectual Property and Director of the USPTO.
  • Established in 1990, the Collegiate Inventors Competition is a program of the National Inventors Hall of Fame and is sponsored by the USPTO, Arrow Electronics (Arrow Electronics People's Choice Award), and Honda.

Cyngn Secures Four New Patents for its AI-Powered Autonomous Vehicle Technologies

Retrieved on: 
Thursday, September 14, 2023
United States Patent and Trademark Office, Patent, Safety, 3D printing

MENLO PARK, Calif., Sept. 14, 2023 /PRNewswire/ -- Cyngn Inc. (the "Company" or "Cyngn") (Nasdaq: CYN), a developer of AI-powered autonomous driving solutions for industrial applications, today announced the issuance of four new patents granted by the United States Patent and Trademark Office (USPTO) for its autonomous vehicle technologies.

Key Points: 
  • Since August 2023, Cyngn has been granted four additional patents, bringing total US patents granted to 14
    MENLO PARK, Calif., Sept. 14, 2023 /PRNewswire/ -- Cyngn Inc. (the "Company" or "Cyngn") (Nasdaq: CYN), a developer of AI-powered autonomous driving solutions for industrial applications, today announced the issuance of four new patents granted by the United States Patent and Trademark Office (USPTO) for its autonomous vehicle technologies.
  • "The additions of Cyngn's four new patents reaffirm our commitment to innovation in autonomous technology while ensuring safety and scalability remain at the forefront of our advancements," said Lior Tal, chief executive officer of Cyngn.
  • In August, the Company announced the procurement of four additional patents as a result of their proprietary technology for vehicle sensors, obstacle detection systems, autonomous driving predictions and multi-channel object matching.
  • The publication of four additional patents brings the company's total US patents to 14, further solidifying its position as a pioneer and leader in the autonomous industrial sector.